Why the study?
Is the presence of anti-beta 2GPI antibodies associated with clinical manifestations such as thrombosis in patients with SLE?
Is the presence of anti-beta 2GPI antibodies associated with clinical manifestations such as thrombosis in patients with SLE?
Answers are grounded in this paper and cite their sources.
Enzyme immunoassay for anti-beta 2GPI may be useful in evaluating the risk of thrombosis and monitoring disease activity in patients with SLE.
OBJECTIVE: To investigate whether anticardiolipin antibodies (aCL) in patients with systemic lupus erythematosus (SLE) bind to beta 2-glycoprotein I (beta 2GPI), and to search for a relationship between the presence of IgG and/or IgM anti-beta 2GPI antibody and clinical manifestations in SLE patients. METHODS: IgG and IgM anti-beta 2GPI in 308 Japanese SLE patients were measured using phospholipid-independent enzyme immunoassays. Relationships to clinical histories and to various laboratory data were examined. RESULTS: The values of anti-beta 2GPI and aCL, as measured by conventional enzyme immunoassay, showed a strong correlation, but the anti-beta 2GPI assay was more useful in distinguishing beta 2GPI-dependent aCL from beta 2GPI-independent aCL. The presence of IgG anti-beta 2GPI was associated with an increased frequency of a history of thrombosis. Comparisons of various laboratory data suggested that the titer of anti-beta 2GPI may fluctuate with disease activity. CONCLUSION: The results suggest that pathogenic aCL is directed against structurally altered beta 2GPI and that enzyme immunoassay for anti-beta 2GPI may prove useful in evaluating the risk of thrombosis and monitoring the clinical course in patients with SLE.
No takes yet. Share an insight, caveat, or question.
Tsutsumi et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: